MRNA Investor Relations

Moderna is a biotechnology company that specializes in the development of mRNA (messenger RNA) technology to create innovative medicines and vaccines. The company gained significant recognition for its rapid development of a COVID-19 vaccine, which was one of the first to receive emergency use authorization globally. Moderna’s focus extends beyond vaccines; it aims to leverage its mRNA platform to develop treatments for various diseases, including infectious diseases, cancer, and rare genetic disorders.

Moderna Head of Investor Relations

Lavina Talukdar currently serves as the Senior Vice President and Head of Investor Relations at Moderna. She has held this position since April 2019 and has extensive experience in investment management, particularly in the healthcare sector. Her role involves communicating with investors and stakeholders about Moderna’s financial health, strategic direction, and developments in its product pipeline.

Moderna Investor Relations Email & Contact Us

For inquiries related to investor relations, you can contact Lavina Talukdar at:

Email: Lavina.Talukdar@modernatx.com

Phone: 617-209-5834

Additionally, general investor inquiries can be directed to the email address: ir@modernatx.com

MRNA Last Stock Split

Moderna has executed one stock split in its history. On July 22, 2010, the company conducted a 1-for-4 reverse stock split, meaning for every four shares held, shareholders received one share.

MRNA Investor Relations Website

Investors can find a wealth of information on Moderna’s official investor relations website at investors.modernatx.com. This site includes details about financial results, upcoming events, press releases, and other relevant investor information.